What's Happening?
Eli Lilly has entered into a collaboration with Ascidian Therapeutics to develop RNA exon editors aimed at treating inherited kidney diseases. This partnership, potentially worth over $1.9 billion, focuses on using Ascidian's technology to repair genetic
instructions causing disease. The RNA exon editors can address multiple mutations simultaneously, offering a versatile approach to treating a wide range of genetic diseases. The collaboration will leverage Ascidian's expertise in RNA biology and Lilly's capabilities in genetic medicine to advance treatments for monogenic kidney diseases and potentially expand to other targets.
Why It's Important?
This collaboration represents a significant step forward in the field of genetic medicine, particularly in addressing inherited kidney diseases, which affect millions of Americans. By focusing on RNA exon editing, the partnership aims to provide more effective treatments for diseases with high mutational variance. The ability to replace disease-causing exons with healthy ones could lead to breakthroughs in treating not only kidney diseases but also other genetic disorders. This aligns with Lilly's broader strategy to expand its genetic medicine pipeline, potentially leading to new therapies that could improve patient outcomes and reduce the burden of genetic diseases.
What's Next?
The collaboration will initially focus on undisclosed kidney disease targets, with Ascidian leading discovery and preclinical activities. Lilly will oversee further preclinical work, clinical development, and commercialization. As the partnership progresses, it may expand to include additional targets, leveraging the versatility of RNA exon editing. The success of this collaboration could pave the way for similar partnerships and advancements in genetic medicine, potentially transforming the treatment landscape for various genetic diseases.
